Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ASF1A | Q9Y294 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7561082 | 1.00 | RAB9A (0.56) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7559725 | 0.88 | SMN1; SMN2 (0.57) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7559728 | 0.88 | SMN1; SMN2 (0.57) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7560925 | 0.86 | SMN1; SMN2 (0.59) | RAB9AKMT2AMEN1SMN1; SMN2POLB | |
| SCHEMBL7560930 | 0.86 | SMN1; SMN2 (0.59) | RAB9AKMT2AMEN1SMN1; SMN2POLB | |
| SCHEMBL7560543 | 0.82 | LMNA (0.61) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7560540 | 0.82 | LMNA (0.61) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7678783 | 0.82 | LMNA (0.55) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7562946 | 0.82 | MAPT (0.48) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7533566 | 0.82 | LMNA (0.55) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020091148-A1 | 3-substituted indole antiproliferative angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-07-11 | — | — | US | claimed |
| WO-2002022576-A2 | 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-21 | — | — | WO | claimed |
| US-6323228-B1 | INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES | ABBOTT LABORATORIES | 2001-11-27 | — | — | US | claimed |
| US-20020091148-A1 | 3-substituted indole antiproliferative angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-07-11 | — | — | US | disclosed |
| WO-2002022576-A2 | 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-21 | — | — | WO | disclosed |
| US-6323228-B1 | INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES | ABBOTT LABORATORIES | 2001-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091148-A1 | 3-substituted indole antiproliferative angiogenesis inhibitors | MKI67, FLT4, IDO1 | RAB9A 3961/4885KMT2A 2765/4885MEN1 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.